Final Agenda Released: 3rd China Diabetes & Metabolic Diseases Drug and Device Innovation R&D Conference to Convene in Chengdu
Amid escalating tariff frictions in the global biopharmaceutical sector and ongoing restructuring of industrial supply chains, Chinese innovative pharmaceutical companies are facing unprecedented opportunities and challenges. At this critical juncture, the 3rd Conference on Innovative R&D of Drugs and Devices for Diabetes and Metabolic Diseases will be held on April 26–27 at the InterContinental Chengdu Global Center Paradise Hotel.
Registration is now open. Scan the QR code to register immediately.
Final Agenda Officially Released
In response to shifts in the international economic and trade landscape, the conference has launched its inaugural Licensing and Collaboration Forum, directly addressing the pain points innovative pharmaceutical companies face in their global expansion strategies. The forum features invited leaders from investment institutions who will interpret trends in overseas collaboration, while senior law firm partners will provide detailed insights into the risks and compliance considerations of business development (BD) transactions. A special discussion session will facilitate cross-sector dialogue among clinical experts, capital providers, and corporate representatives to jointly explore pathways for reconstructing value assessment systems, thereby injecting differentiated thinking into pipeline strategic planning.
With targets being highly concentrated, intense competition in R&D has become a prominent challenge in the field of metabolic diseases. Starting from clinical needs, the conference brings together domestic and international enterprises focused on the development of GLP-1 receptor agonists, insulin analogs, and novel multi-target drugs, offering diverse R&D perspectives. Beyond addressing the issue of homogenization, the conference further focuses on how AI technology is reshaping R&D paradigms. It will showcase how large language models such as DeepSeek empower the entire drug development chain, including multi-target drug molecule generation, optimization of clinical development strategies, and support for regulatory decision-making.
We cordially invite industry colleagues to gather at this conference to jointly promote the deep integration of scientific research and clinical practice, accelerate the efficient translation of innovative achievements into clinical applications, contribute Chinese wisdom to the global prevention and control of metabolic diseases, and leverage the power of technology to break the deadlock of chronic disease management. For further collaboration opportunities or suggestions on forum planning, please contact us.
Business Cooperation:
We cordially invite industry colleagues to join us at this conference to foster the deep integration of scientific research and clinical practice, accelerate the efficient translation of innovative achievements into clinical applications, contribute Chinese wisdom to the global prevention and control of metabolic diseases, and leverage the power of technology to break the deadlock of chronic disease management.
For further collaboration inquiries and suggestions on forum settings, please contact us.
Business Cooperation: Yan Dixi 13811506589
Conference Consultation: Duan Mengyu 18811529021